Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fludarabine
Drug ID BADD_D00914
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status approved
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D07966
MeSH ID C024352
PubChem ID 657237
TTD Drug ID D0F2XQ
NDC Product Code 16729-131
UNII P2K93U8740
Synonyms fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine
Chemical Information
Molecular Formula C10H12FN5O4
CAS Registry Number 21679-14-1
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diffuse large B-cell lymphoma recurrent01.15.02.002; 16.28.02.0020.000112%-
Richter's syndrome01.15.02.005; 16.28.02.0050.000336%-
Metastatic squamous cell carcinoma16.16.01.0100.000112%-
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.000280%-
Graft versus host disease in skin10.02.01.062; 12.02.09.031; 23.07.04.0250.000224%-
Graft versus host disease in liver09.01.07.033; 10.02.01.060; 12.02.09.0290.000112%-
Clonal evolution16.32.03.0220.000112%-
Acute graft versus host disease in skin10.02.01.053; 12.02.09.022; 23.07.04.0200.000168%-
Invasive lobular breast carcinoma16.10.01.014; 21.05.01.0220.000112%-
Graft versus host disease in gastrointestinal tract07.11.01.027; 10.02.01.059; 12.02.09.0280.000280%-
Toxic leukoencephalopathy12.03.01.059; 17.13.02.0120.000839%-
Ductal adenocarcinoma of pancreas07.21.09.011; 16.13.10.0060.000112%-
Haemophagocytic lymphohistiocytosis01.05.01.026; 10.02.01.077; 16.32.03.0380.000839%-
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.027---
Immune effector cell-associated neurotoxicity syndrome12.03.01.065; 17.13.01.015; 19.13.01.0060.000168%-
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.000224%-
Juvenile chronic myelomonocytic leukaemia01.10.07.005; 16.01.07.0050.000112%-
Malignant neoplasm of unknown primary site16.16.01.0190.000112%-
Paraneoplastic pemphigus10.04.02.020; 16.32.01.013; 23.03.01.0400.000112%-
Therapy non-responder08.06.01.0630.000616%-
The 9th Page    First    Pre   9    Total 9 Pages